The objective of this work is to identify perturbed metabolic processes characteristic of breast cancer cell lines of the subtypes ER(+), PR(+), and HER2(3+), which could form the basis of the identification of new markers for diagnosis and drug targets. This evidence concerns the gene ERBB2 and breast carcinoma.